HeartFlow Inc. (NASDAQ: HTFL) filed a patent infringement lawsuit against Cleerly Inc. in the United States District Court for the Eastern District of Texas, according to a company statement released April 13.

The Mountain View, California-based medical technology company alleges that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe six HeartFlow patents with priority dates ranging from 2012 to 2018. HeartFlow seeks permanent injunctive relief and damages from the unauthorized use of its technology.

"HeartFlow pioneered a significant medical technology that has touched over 600,000 patients' lives," said John Farquhar, CEO of HeartFlow. "We take seriously our responsibility to protect the intellectual property that supports this field and the clinicians and patients it serves."

HeartFlow claims its patents protect innovations developed years before Cleerly introduced any products. The company maintains a portfolio of over 600 granted patent assets worldwide.

HeartFlow develops AI technology for coronary artery disease diagnosis and management. The company's platform creates 3D models from coronary CTA images to provide insights into plaque location, volume, and composition without invasive procedures.

The technology has been adopted by more than 1,800 institutions globally and has been used to analyze cases for over 600,000 patients worldwide, according to the company statement.